Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEWTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing...
-
-- Initiated Phase 3 Study URIROX-1™ and Phase 2 Study 206 for ALLN-177 in Patients with Severe Hyperoxaluria -- -- Reiterates Guidance for Key Objectives Across Portfolio-- NEWTON, Mass., May 08,...
-
-- Initiated URIROX-1™, First Phase 3 Trial of ALLN-177 in Enteric Hyperoxaluria; Topline Data Expected in Second Half of 2019 – -- Initiated Phase 2 Trial of ALLN-177 for Patients with Primary...
-
NEWTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing...
-
URIROX-1TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population - Topline Data Expected in Second Half of 2019 -ALLN-177 has Potential to be the First...
-
-- Successfully Completed Initial Public Offering, Raising $74.9 Million in Gross Proceeds -- Presented Final Results from Phase 2 Trials of ALLN-177 in Secondary Hyperoxaluria at ASN Kidney Week...
-
NEWTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme...